Earnings ·
Amarin Reports Q3 Net Income of $0.2M on Revenue Decline to $39.6M
AMRNAmarin Corp Plcuk
Amarin Corporation plc reported a net income of $0.2 million for the third quarter ended September 30, 2026, marking its first profitable quarter in over two years. Total net revenue declined 20% to $39.6 million from $49.7 million in the prior-year period, driven by a 30% drop in U.S. VASCEPA sales due to generic competition and lower European licensing purchases. Operating expenses fell 44% to $18.5 million following completed restructuring initiatives. The company generated $9.2 million in net cash from operating activities and ended the quarter with $323.4 million in cash, remaining debt-free. Amarin Corporation plc develops and commercializes cardiovascular therapies, primarily VASCEPA.